Sophia Randolph

10.5k total citations · 3 hit papers
69 papers, 6.8k citations indexed

About

Sophia Randolph is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Sophia Randolph has authored 69 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 22 papers in Immunology. Recurrent topics in Sophia Randolph's work include Advanced Breast Cancer Therapies (33 papers), HER2/EGFR in Cancer Research (16 papers) and Phagocytosis and Immune Regulation (14 papers). Sophia Randolph is often cited by papers focused on Advanced Breast Cancer Therapies (33 papers), HER2/EGFR in Cancer Research (16 papers) and Phagocytosis and Immune Regulation (14 papers). Sophia Randolph collaborates with scholars based in United States, South Korea and Germany. Sophia Randolph's co-authors include Richard S. Finn, Dennis J. Slamon, Nadia Harbeck, Karen A. Gelmon, Seock‐Ah Im, Hope S. Rugo, Eric Gauthier, Miguel Martín, Stephen E. Jones and Véronique Dièras and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sophia Randolph

66 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Palbociclib and Letrozole in Advanced Breast Cancer

2016 1.9k citations Richard S. Finn, Nadia Harbeck et al. New England Journal of Medicine profile →
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Richard S. Finn, John Crown et al. The Lancet Oncology profile →
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

2015 1.1k citations Nicholas C. Turner, Jungsil Ro et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Sophia Randolph

Since Specialization

Citations

This map shows the geographic impact of Sophia Randolph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophia Randolph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophia Randolph more than expected).

Fields of papers citing papers by Sophia Randolph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sophia Randolph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophia Randolph. The network helps show where Sophia Randolph may publish in the future.

Co-authorship network of co-authors of Sophia Randolph

This figure shows the co-authorship network connecting the top 25 collaborators of Sophia Randolph. A scholar is included among the top collaborators of Sophia Randolph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sophia Randolph. Sophia Randolph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC). 2025 ·Journal of Clinical Oncology ·Kohei Shitara, Zev A. Wainberg, Josep Tabernero, Eric Van Cutsem, Clélia Coutzac, (unknown), Jeeyun Lee, Sun Young Rha, Yoon‐Koo Kang, (unknown), (unknown), Feng Jin, Alison Forgie, Jaume Pons, Athanasios C. Tsiatis, Sophia Randolph, Keun Wook Lee	3
2	Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results. 2024 ·Journal of Clinical Oncology ·Samuel A. Funt, Petros Grivas, Xīn Gào, Daniel A. Vaena, Tian Zhang, Matthew I. Milowsky, (unknown), Harry Liu, Kimberly Tipton, (unknown), Feng Jin, Alison Forgie, Sophia Randolph, Athanasios C. Tsiatis, (unknown)	1
3	SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer 2021 ·Annals of Oncology ·Hyun Cheol Chung, Kyungwon Lee, (unknown), Justin F. Gainor, (unknown), Laura Q.M. Chow, Wells A. Messersmith, (unknown), Pierre Squifflet, Feng Jin, Alison Forgie, Hong Wan, Jaime Pons, Sophia Randolph, P. LoRusso	10
4	ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma 2020 ·Blood ·Tae Min Kim, Nehal J. Lakhani, Justin F. Gainor, Manali Kamdar, (unknown), Pierre Squifflet, Feng Jin, Alison Forgie, Hong Wan, Jaume Pons, Sophia Randolph, Won Seog Kim	23
5	ALX148 Is a High Affinity Sirpα Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models 2017 ·Blood ·Steven E. Kauder, Tracy C. Kuo, Amy Chen, Ons Harrabi, (unknown), Laura V. Doyle, Sangeetha Bollini, Bora Han, Emma Sangalang, (unknown), Sophia Randolph, Jaume Pons, Hong Wan	8
6	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 2016 ·Breast Cancer Research ·Richard S. Finn, John Crown, Johannes Ettl, Marcus Schmidt, Igor Bondarenko, István Láng, Tamás Pintér, Katalin Boér, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett, Dennis J. Slamon	136
7	Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer breakdown → 2015 ·New England Journal of Medicine ·Nicholas C. Turner, Jungsil Ro, Fabrice André, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Sibylle Loibl, Cynthia Huang Bartlett, Ke Zhang, C. Giorgetti, Sophia Randolph, María Koehler, Massimo Cristofanilli	1111
8	Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18. 2015 ·Journal of Clinical Oncology ·Richard S. Finn, John Crown, Johannes Ettl, Tamás Pintér, Anu Thummala, Yaroslav Shparyk, Ravi Patel, Sophia Randolph, Sindy Kim, Xin Huang, Yuqiu Jiang, Cynthia Huang Bartlett, Dennis J. Slamon	1
9	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study breakdown → 2014 ·The Lancet Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Camilla Fowst, Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	1412
10	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines 2014 ·Pigment Cell & Melanoma Research ·Richard J. Young, Kelly Waldeck, Claire Martin, (unknown), Donald P. Cameron, Laura Kirby, Hongdo Do, Catherine Mitchell, Carleen Cullinane, Wendy Liu, Stephen B. Fox, Ken Dutton‐Regester, Nicholas K. Hayward, Nicholas Jene, Alexander Dobrovic, Richard B. Pearson, James G. Christensen, Sophia Randolph, Grant A. McArthur, Karen E. Sheppard	154
11	Phase II Study of Palbociclib (PD-0332991) + Letrozole vs Letrozole Alone in First-Line ER + /HER2- Advanced Breast Cancer 2013 ·Annals of Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, Jungsil Ro, Xin Huang, S. T. Kim, Sophia Randolph, Dennis J. Slamon	5
12	Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia 2012 ·Molecular Cancer Therapeutics ·Jeremy B. Samon, Mireia Castillo-Martín, Michael Hadler, (unknown), Elisabeth Paietta, Janis Racevskis, Peter H. Wiernik, Jacob M. Rowe, John Jakubczak, Sophia Randolph, Carlos Cordon‐Cardo, Adolfo A. Ferrando	86
13	100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc) 2012 ·Annals of Oncology ·Richard S. Finn, John Crown, Katalin Boér, István Láng, (unknown), Aurora Breazna, Steffan N. Ho, (unknown), Sophia Randolph, DJ Slamon	30
14	Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer 2011 ·Clinical Cancer Research ·Keith T. Flaherty, Patricia LoRusso, Angela DeMichele, Vandana G. Abramson, Rachel Courtney, Sophia Randolph, M. Naveed Shaik, Keith D. Wilner, Peter J. O’Dwyer, Gary K. Schwartz	295
15	A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. 2011 ·Journal of Clinical Oncology ·Wells A. Messersmith, P. LoRusso, (unknown), Arvind Dasari, (unknown), M. Naveed Shaik, Rachel Courtney, Sophia Randolph, Geoffrey I. Shapiro	4
16	Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design 2010 ·Molecular Cancer Therapeutics ·Ping Wei, Marlena Walls, Ming Qiu, (unknown), Robert H. Denlinger, Anthony Wong, (unknown), Jitesh P. Jani, Natilie Hosea, Michelle Sands, Sophia Randolph, Tod Smeal	158
17	Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma 2008 ·Cancer Research ·Valeria R. Fantin, Andrey Loboda, Cloud P. Paweletz, Ronald C. Hendrickson, Jacqueline W. Pierce, Jennifer A. Roth, Lixia Li, (unknown), Susan Korenchuk, Xiaoli Hou, Elizabeth A. Harrington, Sophia Randolph, John F. Reilly, Christopher Ware, Marshall E. Kadin, Stanley R. Frankel, Victoria M. Richon	138
18	Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma 2008 ·Annals of Oncology ·Michael Crump, Bertrand Coiffier, Eric D. Jacobsen, Linda Sun, Justin L. Ricker, Huafeng Xie, Stanley R. Frankel, Sophia Randolph, Bruce D. Cheson	139
19	Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): Final results of a phase II trial 2007 ·Journal of Clinical Oncology ·Michael Crump, Bertrand Coiffier, Eric D. Jacobsen, Lin Sun, Justin L. Ricker, Huafeng Xie, SR Frankel, Sophia Randolph, Bruce D. Cheson	7
20	The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation 2003 ·Blood Reviews ·Stanley R. Riddell, Carolina Berger, Makoto Murata, Sophia Randolph, Edus H. Warren	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact